Free Trial
→ Read now. Do not delete. You’ve been warned. (From Porter & Company) (Ad)tc pixel Free BLAC Stock Alerts

Bellevue Life Sciences Acquisition (BLAC) Competitors

Bellevue Life Sciences Acquisition logo
$0.50 -0.01 (-1.59%)
As of 05/22/2026
Compare

BLAC vs. INBS, TNON, NDRA, NXL, and NVNO

Should you buy Bellevue Life Sciences Acquisition stock or one of its competitors? MarketBeat compares Bellevue Life Sciences Acquisition with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bellevue Life Sciences Acquisition include Intelligent Bio Solutions (INBS), Tenon Medical (TNON), ENDRA Life Sciences (NDRA), Nexalin Technology (NXL), and enVVeno Medical (NVNO). These companies are all part of the "medical equipment" industry.

How does Bellevue Life Sciences Acquisition compare to Intelligent Bio Solutions?

Bellevue Life Sciences Acquisition (NASDAQ:BLAC) and Intelligent Bio Solutions (NASDAQ:INBS) are both small-cap medical equipment companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bellevue Life Sciences Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Intelligent Bio Solutions
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Bellevue Life Sciences Acquisition has higher earnings, but lower revenue than Intelligent Bio Solutions.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bellevue Life Sciences AcquisitionN/AN/AN/AN/AN/A
Intelligent Bio Solutions$3.05M2.01-$10.57M-$12.22N/A

Bellevue Life Sciences Acquisition has a net margin of 0.00% compared to Intelligent Bio Solutions' net margin of -296.73%. Bellevue Life Sciences Acquisition's return on equity of 0.00% beat Intelligent Bio Solutions' return on equity.

Company Net Margins Return on Equity Return on Assets
Bellevue Life Sciences AcquisitionN/A N/A N/A
Intelligent Bio Solutions -296.73%-176.09%-89.71%

55.3% of Bellevue Life Sciences Acquisition shares are held by institutional investors. Comparatively, 33.0% of Intelligent Bio Solutions shares are held by institutional investors. 33.7% of Bellevue Life Sciences Acquisition shares are held by company insiders. Comparatively, 1.3% of Intelligent Bio Solutions shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Intelligent Bio Solutions had 1 more articles in the media than Bellevue Life Sciences Acquisition. MarketBeat recorded 1 mentions for Intelligent Bio Solutions and 0 mentions for Bellevue Life Sciences Acquisition. Intelligent Bio Solutions' average media sentiment score of 1.19 beat Bellevue Life Sciences Acquisition's score of 0.00 indicating that Intelligent Bio Solutions is being referred to more favorably in the news media.

Company Overall Sentiment
Bellevue Life Sciences Acquisition Neutral
Intelligent Bio Solutions Positive

Bellevue Life Sciences Acquisition has a beta of -0.08, indicating that its share price is 108% less volatile than the broader market. Comparatively, Intelligent Bio Solutions has a beta of 4.24, indicating that its share price is 324% more volatile than the broader market.

Summary

Bellevue Life Sciences Acquisition and Intelligent Bio Solutions tied by winning 5 of the 10 factors compared between the two stocks.

How does Bellevue Life Sciences Acquisition compare to Tenon Medical?

Bellevue Life Sciences Acquisition (NASDAQ:BLAC) and Tenon Medical (NASDAQ:TNON) are both small-cap medical equipment companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

Bellevue Life Sciences Acquisition has higher earnings, but lower revenue than Tenon Medical.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bellevue Life Sciences AcquisitionN/AN/AN/AN/AN/A
Tenon Medical$3.94M2.11-$12.56M-$1.29N/A

In the previous week, Tenon Medical had 1 more articles in the media than Bellevue Life Sciences Acquisition. MarketBeat recorded 1 mentions for Tenon Medical and 0 mentions for Bellevue Life Sciences Acquisition. Bellevue Life Sciences Acquisition's average media sentiment score of 0.00 equaled Tenon Medical'saverage media sentiment score.

Company Overall Sentiment
Bellevue Life Sciences Acquisition Neutral
Tenon Medical Neutral

55.3% of Bellevue Life Sciences Acquisition shares are held by institutional investors. Comparatively, 22.7% of Tenon Medical shares are held by institutional investors. 33.7% of Bellevue Life Sciences Acquisition shares are held by company insiders. Comparatively, 0.3% of Tenon Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bellevue Life Sciences Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Tenon Medical
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Bellevue Life Sciences Acquisition has a beta of -0.08, indicating that its share price is 108% less volatile than the broader market. Comparatively, Tenon Medical has a beta of 1.28, indicating that its share price is 28% more volatile than the broader market.

Bellevue Life Sciences Acquisition has a net margin of 0.00% compared to Tenon Medical's net margin of -270.09%. Bellevue Life Sciences Acquisition's return on equity of 0.00% beat Tenon Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Bellevue Life Sciences AcquisitionN/A N/A N/A
Tenon Medical -270.09%-907.60%-110.17%

Summary

Bellevue Life Sciences Acquisition and Tenon Medical tied by winning 5 of the 10 factors compared between the two stocks.

How does Bellevue Life Sciences Acquisition compare to ENDRA Life Sciences?

Bellevue Life Sciences Acquisition (NASDAQ:BLAC) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap medical equipment companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, profitability and media sentiment.

In the previous week, Bellevue Life Sciences Acquisition's average media sentiment score of 0.00 equaled ENDRA Life Sciences'average media sentiment score.

Company Overall Sentiment
Bellevue Life Sciences Acquisition Neutral
ENDRA Life Sciences Neutral

Bellevue Life Sciences Acquisition has a beta of -0.08, suggesting that its stock price is 108% less volatile than the broader market. Comparatively, ENDRA Life Sciences has a beta of -0.11, suggesting that its stock price is 111% less volatile than the broader market.

ENDRA Life Sciences has a consensus price target of $30.00, indicating a potential upside of 435.71%. Given ENDRA Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe ENDRA Life Sciences is more favorable than Bellevue Life Sciences Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bellevue Life Sciences Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
ENDRA Life Sciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bellevue Life Sciences AcquisitionN/AN/AN/AN/AN/A
ENDRA Life SciencesN/AN/A-$7.03M-$8.15N/A

Bellevue Life Sciences Acquisition's return on equity of 0.00% beat ENDRA Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Bellevue Life Sciences AcquisitionN/A N/A N/A
ENDRA Life Sciences N/A -433.64%-204.58%

55.3% of Bellevue Life Sciences Acquisition shares are owned by institutional investors. Comparatively, 1.2% of ENDRA Life Sciences shares are owned by institutional investors. 33.7% of Bellevue Life Sciences Acquisition shares are owned by company insiders. Comparatively, 10.0% of ENDRA Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Bellevue Life Sciences Acquisition beats ENDRA Life Sciences on 5 of the 8 factors compared between the two stocks.

How does Bellevue Life Sciences Acquisition compare to Nexalin Technology?

Nexalin Technology (NASDAQ:NXL) and Bellevue Life Sciences Acquisition (NASDAQ:BLAC) are both small-cap medical equipment companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nexalin Technology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Bellevue Life Sciences Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Nexalin Technology had 3 more articles in the media than Bellevue Life Sciences Acquisition. MarketBeat recorded 3 mentions for Nexalin Technology and 0 mentions for Bellevue Life Sciences Acquisition. Nexalin Technology's average media sentiment score of 0.36 beat Bellevue Life Sciences Acquisition's score of 0.00 indicating that Nexalin Technology is being referred to more favorably in the media.

Company Overall Sentiment
Nexalin Technology Neutral
Bellevue Life Sciences Acquisition Neutral

0.7% of Nexalin Technology shares are held by institutional investors. Comparatively, 55.3% of Bellevue Life Sciences Acquisition shares are held by institutional investors. 25.3% of Nexalin Technology shares are held by company insiders. Comparatively, 33.7% of Bellevue Life Sciences Acquisition shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Bellevue Life Sciences Acquisition has lower revenue, but higher earnings than Nexalin Technology.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nexalin Technology$300K25.91-$8.22M-$0.47N/A
Bellevue Life Sciences AcquisitionN/AN/AN/AN/AN/A

Nexalin Technology has a beta of 3.56, indicating that its stock price is 256% more volatile than the broader market. Comparatively, Bellevue Life Sciences Acquisition has a beta of -0.08, indicating that its stock price is 108% less volatile than the broader market.

Bellevue Life Sciences Acquisition has a net margin of 0.00% compared to Nexalin Technology's net margin of -3,018.12%. Bellevue Life Sciences Acquisition's return on equity of 0.00% beat Nexalin Technology's return on equity.

Company Net Margins Return on Equity Return on Assets
Nexalin Technology-3,018.12% -191.88% -166.43%
Bellevue Life Sciences Acquisition N/A N/A N/A

Summary

Nexalin Technology and Bellevue Life Sciences Acquisition tied by winning 5 of the 10 factors compared between the two stocks.

How does Bellevue Life Sciences Acquisition compare to enVVeno Medical?

enVVeno Medical (NASDAQ:NVNO) and Bellevue Life Sciences Acquisition (NASDAQ:BLAC) are both small-cap medical equipment companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment.

enVVeno Medical has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market. Comparatively, Bellevue Life Sciences Acquisition has a beta of -0.08, indicating that its share price is 108% less volatile than the broader market.

Bellevue Life Sciences Acquisition's return on equity of 0.00% beat enVVeno Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
enVVeno MedicalN/A -66.39% -60.42%
Bellevue Life Sciences Acquisition N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
enVVeno MedicalN/AN/A-$19.47M-$25.54N/A
Bellevue Life Sciences AcquisitionN/AN/AN/AN/AN/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
enVVeno Medical
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Bellevue Life Sciences Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

34.7% of enVVeno Medical shares are held by institutional investors. Comparatively, 55.3% of Bellevue Life Sciences Acquisition shares are held by institutional investors. 15.0% of enVVeno Medical shares are held by company insiders. Comparatively, 33.7% of Bellevue Life Sciences Acquisition shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, enVVeno Medical's average media sentiment score of 0.00 equaled Bellevue Life Sciences Acquisition'saverage media sentiment score.

Company Overall Sentiment
enVVeno Medical Neutral
Bellevue Life Sciences Acquisition Neutral

Summary

Bellevue Life Sciences Acquisition beats enVVeno Medical on 4 of the 6 factors compared between the two stocks.

Get Bellevue Life Sciences Acquisition News Delivered to You Automatically

Sign up to receive the latest news and ratings for BLAC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BLAC vs. The Competition

Export
MetricBellevue Life Sciences AcquisitionHolding Offices IndustryManufacturing SectorNASDAQ Exchange
Market Cap$2.03M$248.95M$4.26B$12.34B
Dividend YieldN/A3.22%5.93%5.28%
P/E RatioN/A2.2721.9025.66
Price / SalesN/A0.14180.5986.31
Price / CashN/A123.3055.6856.67
Price / BookN/A25.6634.857.14
Net IncomeN/A-$8.98M$112.32M$335.98M
7 Day Performance-3.96%-0.03%3.54%4.11%
1 Month Performance-27.56%0.66%3.59%2.52%
1 Year Performance-56.72%0.99%15.80%35.04%

Bellevue Life Sciences Acquisition Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BLAC
Bellevue Life Sciences Acquisition
N/A$0.50
-1.6%		N/A-56.7%$2.03MN/AN/AN/A
INBS
Intelligent Bio Solutions
0.8776 of 5 stars		$4.01
-2.4%		N/A-81.8%$8.23M$3.58MN/A10
TNON
Tenon Medical
0.6895 of 5 stars		$0.71
-2.4%		N/A-35.4%$8.18M$3.94MN/A8
NDRA
ENDRA Life Sciences
2.3228 of 5 stars		$5.05
-12.0%		$30.00
+494.1%		+80.1%$7.12MN/AN/A20
NXL
Nexalin Technology
0.6548 of 5 stars		$0.34
+0.7%		N/A-69.3%$7.00M$275.58KN/A3

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:BLAC) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...
Eagle Publishing | Sponsoredtc pixel
June 4: The day smart money moves (not June 12)
Everyone is watching June 12 - the SpaceX listing date. The real deadline is June 4, when Goldman Sachs, Morga...
Behind the Markets | Sponsoredtc pixel
My crisis of conscience
Emmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...
Porter & Company | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Opportunity Forming in a U.S. Supply-Chain Weak Spot?
America has a supply-chain problem with graphite - demand is climbing while dependence on foreign sources rema...
i2i Marketing Group, LLC | Sponsoredtc pixel
Skip the Line Opportunity: The SpaceX IPO
Former tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...
Brownstone Research | Sponsoredtc pixel